Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients With IPF (Businesswire) - Oct 8, 2026 - "The trial met its primary endpoint with taladegib demonstrating a statistically significant improvement in ppFVC over 24 weeks relative to placebo. Treatment with taladegib resulted in an increase in ppFVC from baseline at Week 24, which reflects improvements in lung function. Notably, a pre-specified analysis of lung function while patients remained on treatment showed that continued treatment with taladegib resulted in a sustained improvement from baseline in ppFVC over 24 weeks...Patients who received taladegib experienced significant improvement compared with placebo across several quantitative biomarkers of IPF severity on HRCT, including TLC, percent quantitative total interstitial lung disease (%QILD), and percent quantitative lung fibrosis (%QLF). For each of these HRCT measures, patients treated with taladegib showed improvements from baseline at Week 24."
P2b data • Idiopathic Pulmonary Fibrosis
|